Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumors

Antoine Italiano; Teresa García Manrique; Enrique Grande Pulido; Katie Kerrigan; Aude Fléchon; Julia Martínez Pérez; Bogdan Żurawski; Muhammad Furqan; Oscar Juan-Vidal; Ulka Vaishampayan; Charlene Fares; Bruno Fang; Brian Vicuna; Laurent Greillier; Vivek Subbiah; Mei Dong; Kai Song; Yiran Zhang; Young Kim; Luis Paz-Ares

doi:10.3389/fonc.2026.1786385

Back

Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumors

Journal article

Open access

Peer reviewed

Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumors

Antoine Italiano, Teresa García Manrique, Enrique Grande Pulido, Katie Kerrigan, Aude Fléchon, Julia Martínez Pérez, Bogdan Żurawski, Muhammad Furqan, Oscar Juan-Vidal, Ulka Vaishampayan, …

Frontiers in oncology, Vol.16, 1786385

04/01/2026

DOI: 10.3389/fonc.2026.1786385

PMCID: PMC13143664

PMID: 42100424

Files and links (1)

url

https://doi.org/10.3389/fonc.2026.1786385View

Published (Version of record) Open Access

Abstract

BackgroundNovel treatments are needed to improve the poor prognosis of metastatic cancers. The ELEVATE Lung&UC study evaluated magrolimab plus docetaxel in patients with metastatic non-small cell lung cancer (mNSCLC), metastatic small cell lung cancer (mSCLC), and metastatic urothelial carcinoma (mUC).MethodsThis phase II, open-label, multi-arm study enrolled patients who had received 1–2 (mNSCLC, mSCLC) or 2–3 prior lines of therapy (mUC) in the locally advanced/metastatic setting. A safety run-in (SRI) cohort (mNSCLC/mSCLC/mUC) followed by a phase II cohort (three groups: mNSCLC, mSCLC, mUC) were planned. Primary endpoints were incidence of treatment-emergent adverse events (TEAEs; SRI and phase II) and objective response rate (ORR; phase II).ResultsThe SRI cohort (n = 9) had no dose-limiting toxicities. In phase II (mNSCLC, 29 patients; mSCLC, 42 patients; mUC, 26 patients), ORRs were 17.2% (mNSCLC), 4.8% (mSCLC), and 3.8% (mUC). Grade ≥3 magrolimab-related TEAE rates were 48.3% (mNSCLC), 47.6% (mSCLC), and 57.7% (mUC). A fatal TEAE suspected as magrolimab related (intracranial hemorrhage) occurred in one patient with mSCLC and brain metastasis (phase II). The study was closed early, which limited the interpretation of results due to short follow-up and limited endpoint maturity.DiscussionAdding magrolimab to docetaxel had manageable toxicity but no meaningful improvement in efficacy. These results provide insight into the safety and efficacy of anti-CD47–containing therapies and reinforce the need for treatments that address the unmet needs of patients with previously treated metastatic solid tumors.

anti-CD47

docetaxel

magrolimab

metastatic non-small cell lung cancer

metastatic small cell lung cancer

metastatic urothelial carcinoma

Details

Title: Subtitle: Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumors
Creators: Antoine Italiano - Institut Bergonié
Teresa García Manrique - Hospital Universitario Virgen Macarena
Enrique Grande Pulido - MD Anderson Cancer Center Madrid
Katie Kerrigan - Huntsman Cancer Institute
Aude Fléchon - Centre Léon Bérard
Julia Martínez Pérez - Hospital Universitario Virgen del Rocío
Bogdan Żurawski - Centrum Onkologii
Muhammad Furqan - University of Iowa
Oscar Juan-Vidal - Hospital Universitari i Politècnic La Fe
Ulka Vaishampayan - University of Michigan
Charlene Fares - Virginia Cancer Institute
Bruno Fang - Aston Medical (France)
Brian Vicuna - Comprehensive Cancer Centers of Nevada
Laurent Greillier - Assistance Publique Hôpitaux de Marseille
Vivek Subbiah - The University of Texas MD Anderson Cancer Center
Mei Dong - Gilead Sciences (United States)
Kai Song - Gilead Sciences (United States)
Yiran Zhang - Gilead Sciences (United States)
Young Kim - Gilead Sciences (United States)
Luis Paz-Ares - Hospital Universitario 12 De Octubre
Resource Type: Journal article
Publication Details: Frontiers in oncology, Vol.16, 1786385
DOI: 10.3389/fonc.2026.1786385
PMID: 42100424
PMCID: PMC13143664
NLM abbreviation: Front Oncol
ISSN: 2234-943X
eISSN: 2234-943X
Publisher: Frontiers Media S.A
Grant note: Gilead Sciences
The author(s) declared that financial support was received for this work and/or its publication. This study was sponsored by Gilead Sciences, Inc. Medical writing and editorial assistance were funded by Gilead Sciences, Inc.
Language: English
Date published: 04/01/2026
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9985157605502771

Metrics

1 Record Views